一种与甲福明相关的同时发生的乳酸和优糖糖尿病酸的病例
Daisuke Tomita1, Yuuki Bamba1, Naoko Kuwabara2
1Advanced Disaster Medical and Emergency Critical Care Center, Niigata University Medical and Dental Hospital, Niigata, Japan.
The Journal of emergency medicine
|June 19, 2025
概括
甲胺和SGLT2抑制剂在2型糖尿病中常见,但可能导致危险的酸性化. 这一案例凸显了急诊医生需要快速区分甲胺相关的乳酸症 (MALA) 和euglycemic糖尿病酸症 (euDKA) 的必要性.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
背景情况:
- 建议在2型糖尿病中使用甲福明和SGLT2抑制剂的联合治疗,特别是在心血管或脏疾病的患者中.
- 增加这些药物的使用增加了危及生命的酸性疾病的风险:甲胺相关的乳酸性酸性疾病 (MALA) 和euglycemic糖尿病酸性酸性疾病 (euDKA).
- 迅速区分和独特的治疗对于管理这些罕见但严重的并发症至关重要.
研究的目的:
- 介绍一个患有MALA和eudka的病人的案例.
- 强调在急诊部识别和管理这些独特的酸性紧急情况的重要性.
主要方法:
- 一个50多岁的女性患有慢性心力衰竭和2型糖尿病的病例报告.
- 在流体限制后,患者呈现严重的代谢酸症,脱水和其他关键症状.
- 诊断涉及通过实验室发现和对治疗的反应来区分MALA和eudka.
主要成果:
- 最初的呈现表明MALA,这部分改善了血液透析.
- 持续的离子间隙和升高的β-基酸盐证实了同时存在的eUDKA.
- 持续的胰岛素输注消除了代谢异常,导致患者在没有后果的情况下恢复.
结论:
- 马拉和eudka同时发生的情况很少见,但至关重要,需要具体的诊断和治疗策略.
- 应急医生必须意识到这些潜在的并发症,由于越来越多地使用甲胺和SGLT2抑制剂.
- 及时识别和管理对于有利的患者结果至关重要.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Hypoglycemia and Glucagon
351
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
351
Diabetes: Symptoms, Diagnosis, and Complications
709
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
709
Pathophysiology of Diabetes
1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274


